![Merck to develop mAb through $10.8 billion acquisition - monoclonal antibody development](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/monoclonal-antibody-immune-diseases-375x211.jpg)
Prometheus is a clinical-stage biotechnology company. "I look forward to working with the Prometheus team to establish a new paradigm of precision treatment for immune diseases," commented Dr
According to Merck’s Chairman and Chief Executive Officer,
Anti-TL1A monoclonal antibody for autoimmune conditions
PRA023 is directed to tumour necrosis factor (TNF)-like ligand 1A (TL1A), a target associated with both intestinal inflammation and fibrosis. It binds both soluble and membrane associated human TL1A with high affinity and specificity.
"By applying a portfolio of powerful analytic tools to a comprehensive collection of IBD samples, Prometheus identified important disease insights that have now yielded a promising late-stage candidate," added Dr
In
- ARTEMIS-UC, a Phase II study evaluating safety and efficacy in patients with moderate to severely active UC
-
APOLLO-CD, a Phase IIA study evaluating safety and efficacy in patients with moderate to severe CD. The findings were recently presented at the 18th
Congress of European Crohn's andColitis Organisation (ECCO).
Further details of the transaction
Under the agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus. The acquisition is subject to
Closing of the proposed transaction is expected in the third quarter of 2023 and is subject to certain conditions. This includes the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.
The post Merck to develop mAb through
© Russell Publishing Limited, 2023. All Rights Reserved., source